论文部分内容阅读
目的探讨宫颈癌患者外周血核苷酸切除修复交叉互补1(ERCC1)基因多态性对顺铂新辅助化学治疗(简称化疗)疗效的影响。方法选择2010年3月至2014年6月医院收治的宫颈癌患者80例,根据外周血ERCC1基因表达的不同分为CC组和TT组,各40例。两组患者均给予紫杉醇联合顺铂化疗,21 d为1个周期,共治疗6个周期。治疗结束时比较两组患者的近期疗效、中位生存期、中位进展时间、2年生存率,记录不良反应的发生情况。结果治疗后,TT组近期疗效52.50%,CC组近期疗效为67.50%,CC组显著优于对照组,差异有统计学意义(P<0.05);CC组患者的中位进展时间、中位生存期以及2年生存率均显著高于TT组,差异均具有统计学意义(P<0.05)。治疗后,两组患者血清中CYFRA21-1及SCC-Ag表达均较治疗前有所下降,且CC组下降程度优于TT组,差异均具有统计学意义(P<0.05)。两组患者各方面不良反应发生率结果均无显著性差异(P>0.05)。结论 ERCC1 C19007T表达为C/C型的患者相比较表达为T/T型的患者临床疗效更好,其中位进展时间、中位生存期均较长,2年生存率较高,化疗后血清中特异肿瘤标志物的表达可显著降低,且不良反应发生率相当。
Objective To investigate the effect of nucleotide excision repair cross-complementarity 1 (ERCC1) gene polymorphism on the efficacy of neoadjuvant chemotherapy (abbreviated as chemotherapy) in patients with cervical cancer. Methods Eighty patients with cervical cancer admitted from March 2010 to June 2014 in our hospital were divided into CC group and TT group according to the expression of ERCC1 gene in peripheral blood. Both groups were given paclitaxel combined with cisplatin chemotherapy, 21 d for a cycle, a total of 6 cycles. At the end of treatment, the short-term efficacy, median survival time, median progression time, 2-year survival rate and incidence of adverse reactions were compared between the two groups. Results After treatment, the short-term effect was 52.50% in the TT group and 67.50% in the CC group. The CC group was significantly better than the control group (P <0.05). The median progression time, median survival time Stage and 2-year survival rates were significantly higher than the TT group, the difference was statistically significant (P <0.05). After treatment, the serum levels of CYFRA21-1 and SCC-Ag in both groups decreased compared with that before treatment, and the degree of decline in CC group was better than that in TT group. The difference was statistically significant (P <0.05). There was no significant difference between the two groups in the incidence of adverse reactions in all aspects (P> 0.05). Conclusions Patients with ERCC1 C19007T expression in type C / C are better than patients with T / T expression in type C / C, with longer median progression time and longer median survival and higher 2-year survival rate The expression of specific tumor markers can be significantly reduced, and the incidence of adverse reactions was comparable.